RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www-thieme-connect-de.accesdistant.sorbonne-universite.fr/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2025; 45(01): 122-131
DOI: 10.1055/s-0044-1791579
DOI: 10.1055/s-0044-1791579
Invited Review
Immune-Mediated Neuropathies: Top 10 Clinical Pearls
Funding This study was funded by Michael D. Rothman CIDP Research Fund.
Abstract
Immune-mediated neuropathies encompass a range of neurological disorders, including chronic inflammatory demyelinating polyradiculoneuropathy, Guillain–Barré syndrome, multifocal motor neuropathy, autoimmune autonomic neuropathies, and paranodal nodopathies. Recognizing clinical patterns is key to narrowing the broad range of differential diagnoses in immune-mediated neuropathies. Electrodiagnostic testing is a useful tool to support the diagnosis of immune-mediated neuropathies. Our understanding of autoimmune demyelinating neuropathies is rapidly advancing, particularly with the discovery of nodal and paranodal antibodies. Recent advances in neuropathy treatment include the utilization of neonatal Fc receptors to reduce antibody recycling, and the development of complement inhibitors to reduce inflammatory damage, offering promising new therapeutic avenues. Timely identification of immune-mediated neuropathies is imperative as delay in diagnosis and treatment may lead to irreversible disability.
Publikationsverlauf
Artikel online veröffentlicht:
17. Oktober 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 van Doorn PA, Van den Bergh PYK, Hadden RDM. et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol 2023; 30 (12) 3646-3674
- 2 Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36 (02) 123-133
- 3 Doets AY, Verboon C, van den Berg B. et al; IGOS Consortium. Regional variation of Guillain-Barré syndrome. Brain 2018; 141 (10) 2866-2877
- 4 Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366 (9497) 1653-1666
- 5 Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve 2007; 35 (06) 691-711
- 6 Guillain-Barre Syndrome Study Group. Guillain-Barré syndrome: an Italian multicentre case-control study. Neurol Sci 2000; 21 (04) 229-234
- 7 Leonhard SE, van der Eijk AA, Andersen H. et al; IGOS Consortium. An international perspective on preceding infections in Guillain-Barré syndrome: the IGOS-1000 cohort. Neurology 2022; 99 (12) e1299-e1313
- 8 Mir F, Dar W, Yaqoob A. et al. Seroprevalence of Campylobacter jejuni infection in common subtypes of Guillain–Barre syndrome in Kashmiri population. Egypt J Neurol Psychiatr Neurosurg 2023; 59: 168-174
- 9 Latov N. Campylobacter jejuni infection, anti-ganglioside antibodies, and neuropathy. Microorganisms 2022; 10 (11) 2139
- 10 Dubey D, David WS, Amato AA. et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 2019; 93 (11) e1093-e1103
- 11 Gigli GL, Bax F, Marini A. et al. Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster?. J Neurol 2021; 268 (04) 1195-1197
- 12 Filosto M, Cotti Piccinelli S, Gazzina S. et al. Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry 2021; 92 (07) 751-756
- 13 Choi SA, Hwang J, Lim BC, Chae SA. Incidence of Guillain-Barré syndrome in South Korea during the early COVID-19 pandemic. Front Neurol 2023; 14: 1125455
- 14 Hafsteinsdóttir B, Dalemo E, Elíasdóttir Ó, Ólafsson E, Axelsson M. Decreased incidence of Guillain-Barré syndrome during the COVID-19 pandemic: a retrospective population-based study. Neuroepidemiology 2023; 57 (01) 1-6
- 15 Keddie S, Pakpoor J, Mousele C. et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain 2021; 144 (02) 682-693
- 16 Leonhard SE, Mandarakas MR, Gondim FAA. et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 2019; 15 (11) 671-683
- 17 Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-Barré syndrome: prevalence, clinical spectrum, and outcomes. Neurocrit Care 2020; 32 (01) 113-120
- 18 Luijten LWG, Doets AY, Arends S. et al; IGOS Consortium. Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2023; 94 (04) 300-308
- 19 Walgaard C, Jacobs BC, Lingsma HF. et al; Dutch GBS Study Group. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2021; 20 (04) 275-283
- 20 Doets AY, Lingsma HF, Walgaard C. et al; IGOS Consortium. Predicting outcome in Guillain-Barré syndrome: international validation of the Modified Erasmus GBS Outcome Score. Neurology 2022; 98 (05) e518-e532
- 21 Jaffry M, Menkes DL, Shaikh A. et al. Neonatal Fc receptor inhibitor therapeutics in neuromuscular disease. J Clin Neuromuscul Dis 2023; 24 (04) 188-198
- 22 Zhang H, Ma J, Feng Y. et al. Efgartigimod in the treatment of Guillain-Barré syndrome. J Neurol 2024; 271 (06) 3506-3511
- 23 Karam C. Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome. Identifier: NCT05701189. ClinicalTrials.gov
- 24 Misawa S, Suichi T. Guillain-Barré syndrome: novel treatment by complement inhibition. Clin Exp Neuroimmunol 2020; 11: 90-93
- 25 Misawa S, Kuwabara S, Sato Y. et al; Japanese Eculizumab Trial for GBS (JET-GBS) Study Group. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 2018; 17 (06) 519-529
- 26 Laughlin RS, Dyck PJ, Melton III LJ, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009; 73 (01) 39-45
- 27 Viala K, Maisonobe T, Stojkovic T. et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010; 15 (01) 50-56
- 28 Broers MC, Bunschoten C, Drenthen J. et al. Misdiagnosis and diagnostic pitfalls of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2021; 28 (06) 2065-2073
- 29 Rajabally YA, Peric S, Bozovic I. et al. Antecedent infections and vaccinations in chronic inflammatory demyelinating polyneuropathy: a European collaborative study. Muscle Nerve 2021; 64 (06) 657-661
- 30 Franssen H, Straver DCG. Pathophysiology of immune-mediated demyelinating neuropathies–Part II: Neurology. Muscle Nerve 2014; 49 (01) 4-20
- 31 Van den Bergh PYK, van Doorn PA, Hadden RDM. et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. Eur J Neurol 2021; 28 (11) 3556-3583
- 32 Miranda C, Brannagan TH. Acute/chronic inflammatory polyradiculoneuropathy. In: Younger DS. ed. Handbook of Clinical Neurology:. Elsevier; 2023: 619-633
- 33 Allen J, Gelinas D, Lewis R. et al. Optimizing the use of outcome measures in chronic inflammatory demyelinating polyneuropathy. US Neurology 2017; 13: 26-34
- 34 Breiner A, Barnett C, Bril V. INCAT disability score: a critical analysis of its measurement properties. Muscle Nerve 2014; 50 (02) 164-169
- 35 van Nes SI, Vanhoutte EK, van Doorn PA. et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011; 76 (04) 337-345
- 36 Kodal LS, Witt AM, Pedersen BS, Aagaard MM, Dysgaard T. Prognostic value of neurofilament light in blood in patients with polyneuropathy: a systematic review. J Peripher Nerv Syst 2024; 29 (01) 17-27
- 37 Poser PL, Sajid GS, Beyer L. et al. Serum neurofilament light chain does not detect self-reported treatment-related fluctuations in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 2024; 31 (01) e16023
- 38 Ticau S, Sridharan GV, Tsour S. et al. Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis. Neurology 2021; 96 (03) e412-e422
- 39 Nobile-Orazio E, Cocito D, Jann S. et al; IMC Trial Group. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012; 11 (06) 493-502
- 40 Brannagan III TH. Current treatments of chronic immune-mediated demyelinating polyneuropathies. Muscle Nerve 2009; 39 (05) 563-578
- 41 Cornblath DR, van Doorn PA, Hartung HP. et al; ProCID Investigators. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain 2022; 145 (03) 887-896
- 42 Bril V, Hadden RDM, Brannagan III TH. et al. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial. J Peripher Nerv Syst 2023; 28 (03) 436-449
- 43 van Schaik IN, Bril V, van Geloven N. et al; PATH Study Group. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2018; 17 (01) 35-46
- 44 Allen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology 2015; 85 (06) 498-504
- 45 Kaplan A, Brannagan III TH. Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2017; 55 (04) 476-482
- 46 Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997; 48 (02) 321-328
- 47 Allen JA, Lin J, Basta I. et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2024; 23: 1013-1024
- 48 Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 51 (06) 1735-1738
- 49 Querol L, Lewis R, Hartung H-P. et al. Preliminary efficacy and safety data from the phase 2 trial of riliprubart (SAR445088), a humanized monoclonal antibody targeting complement C1s, in chronic inflammatory demyelinating polyneuropathy (CIDP) (S15.008). Neurology 2024; 102: 2552
- 50 Latov N. Antibody testing in neuropathy associated with anti-myelin-associated glycoprotein antibodies: where we are after 40 years. Curr Opin Neurol 2021; 34 (05) 625-630
- 51 Latov N. Antibodies to glycoconjugates in neuropathy and motor neuron disease. In: Svennerholm L, Asbury AK, Reisfeld RA. , et al., eds. Progress in Brain Research:. Elsevier; 1994: 295-303
- 52 Lozeron P, Ribrag V, Adams D. et al. Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?. J Neurol 2016; 263 (09) 1761-1770
- 53 Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001; 24 (03) 311-324
- 54 Latov N, Brannagan III TH, Sander HW, Gondim FAA. Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials. Arq Neuropsiquiatr 2024; 82 (06) 1-7
- 55 Colchester NTH, Allen D, Katifi HA. et al. Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes. Haematologica 2021; 106 (01) 302-305
- 56 Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2016; 10 (10) CD002827
- 57 Delmont E, Brodovitch A, Kouton L. et al. Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J Neurol 2020; 267 (12) 3664-3672
- 58 Miura Y, Devaux JJ, Fukami Y. et al; CNTN1-CIDP Study Group. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 2015; 138 (Pt 6): 1484-1491
- 59 Uncini A. Autoimmune nodo-paranodopathies 10 years later: clinical features, pathophysiology and treatment. J Peripher Nerv Syst 2023; 28 (Suppl. 03) S23-S35
- 60 Cortese A, Lombardi R, Briani C. et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm 2019; 7 (01) e639
- 61 Devaux JJ, Miura Y, Fukami Y. et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 2016; 86 (09) 800-807
- 62 Cats EA, van der Pol W-L, Piepers S. et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010; 75 (09) 818-825
- 63 Yeh WZ, Dyck PJ, van den Berg LH, Kiernan MC, Taylor BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry 2020; 91 (02) 140-148
- 64 Nobile-Orazio E, Giannotta C, Musset L, Messina P, Léger JM. Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2014; 85 (07) 754-758
- 65 Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. J Peripher Nerv Syst 2010; 15 (04) 295-301
- 66 Gentile L, Russo M, Rodolico C. et al. Multifocal motor neuropathy: long-term treatment with subcutaneous immunoglobulin. J Neurol Sci 2021; 429: 117814
- 67 Carpo M, Cappellari A, Mora G. et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998; 50 (05) 1480-1482
- 68 Nakane S, Koike H, Hayashi T, Nakatsuji Y. Autoimmune autonomic neuropathy: from pathogenesis to diagnosis. Int J Mol Sci 2024; 25 (04) 2296
- 69 Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343 (12) 847-855
- 70 Vernino S, Sandroni P, Singer W, Low PA. Invited article: autonomic ganglia: target and novel therapeutic tool. Neurology 2008; 70 (20) 1926-1932
- 71 Vernino S, Low PA, Lennon VA. Experimental autoimmune autonomic neuropathy. J Neurophysiol 2003; 90 (03) 2053-2059
- 72 Vernino S. Autoimmune autonomic disorders. Continuum (Minneap Minn) 2020; 26 (01) 44-57
- 73 Koike H, Watanabe H, Sobue G. The spectrum of immune-mediated autonomic neuropathies: insights from the clinicopathological features. J Neurol Neurosurg Psychiatry 2013; 84 (01) 98-106
- 74 Imrich R, Vernino S, Eldadah BA, Holmes C, Goldstein DS. Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab. Clin Auton Res 2009; 19 (04) 259-262
- 75 Iodice V, Kimpinski K, Vernino S, Sandroni P, Fealey RD, Low PA. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology 2009; 72 (23) 2002-2008
- 76 Golden EP, Bryarly MA, Vernino S. Seronegative autoimmune autonomic neuropathy: a distinct clinical entity. Clin Auton Res 2018; 28 (01) 115-123
- 77 Sharp L, Vernino S. Paraneoplastic neuromuscular disorders. Muscle Nerve 2012; 46 (06) 841-850
- 78 Zoccarato M, Grisold W, Grisold A, Poretto V, Boso F, Giometto B. Paraneoplastic neuropathies: What's New Since the 2004 recommended diagnostic criteria. Front Neurol 2021; 12: 706169
- 79 Marini A, Bernardini A, Gigli GL. et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 2021; 96 (16) 754-766
- 80 Schneider BJ, Naidoo J, Santomasso BD. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021; 39 (36) 4073-4126
- 81 Farina A, Villagrán-García M, Vogrig A. et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 2024; 23 (01) 81-94
- 82 Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open 2020; 3 (03) e200423
- 83 Ruggiero R, Balzano N, Di Napoli R. et al. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years. Front Immunol 2023; 14: 1134436
- 84 Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol 2019; 130 (08) 1440-1445
- 85 Thawani SP, Brannagan III TH, Lebwohl B, Green PH, Ludvigsson JF. Risk of neuropathy among 28,232 patients with biopsy-verified celiac disease. JAMA Neurol 2015; 72 (07) 806-811
- 86 McKeon A, Lennon VA, Pittock SJ, Kryzer TJ, Murray J. The neurologic significance of celiac disease biomarkers. Neurology 2014; 83 (20) 1789-1796
- 87 Brannagan III TH, Hays AP, Chin SS. et al. Small-fiber neuropathy/neuronopathy associated with celiac disease: skin biopsy findings. Arch Neurol 2005; 62 (10) 1574-1578
- 88 Hadjivassiliou M, Rao DG, Wharton SB, Sanders DS, Grünewald RA, Davies-Jones AG. Sensory ganglionopathy due to gluten sensitivity. Neurology 2010; 75 (11) 1003-1008